A US-based KOL discusses standards of care in bladder cancer and challenges in the current treatment paradigm. The clinical development of novel therapies across all settings is also discussed, alongside areas of unmet need in urothelial carcinoma.

This interview was conducted on Jan. 21, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.  

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.